CBD-Based Epilepsy Treatments in Children May Carry Unknown Developmental Risks

While CBD-enriched cannabis extracts have been successfully used to treat childhood epilepsy, the endocannabinoid system plays critical roles in brain development, and there is insufficient data on the long-term neurodevelopmental effects of early cannabinoid exposure.

Schonhofen, Patrícia et al.·CNS drugs·2018·Moderate EvidenceReview
RTHC-01830ReviewModerate Evidence2018RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

The endocannabinoid system regulates progenitor cell fate, neural differentiation, migration, and survival from early developmental stages. Exogenous cannabinoids including CBD can interact with this system. While CBD has proven therapeutic value for pediatric epilepsy, potential long-term neurodevelopmental effects of modulating the ECS during childhood remain largely unstudied.

Key Numbers

CBD has both endocannabinoid (ECS-mediated) and non-endocannabinoid targets. ECS components are functional from early developmental stages. FDA approved purified CBD from Cannabis for pediatric epilepsy.

How They Did This

Review of current knowledge on CBD-based therapies in pediatric patients, CBD mechanisms of action, and the role of the endocannabinoid system in neurodevelopment.

Why This Research Matters

Thousands of children are now taking CBD for epilepsy. This review raises an important cautionary point: the same system being modulated therapeutically also plays essential roles in brain development, and we do not yet know the long-term consequences.

The Bigger Picture

The tension between CBD's proven short-term benefits for severe epilepsy and its unknown long-term neurodevelopmental effects mirrors a common challenge in pediatric medicine: weighing immediate therapeutic need against potential future risks.

What This Study Doesn't Tell Us

Largely theoretical concerns based on the known biology of the ECS in development. No direct evidence of harm from CBD treatment in children. Extrapolating from basic science to clinical risk involves significant uncertainty.

Questions This Raises

  • ?Do the theoretical developmental risks materialize in children taking CBD long-term?
  • ?Is purified CBD safer than whole-plant extracts for children?
  • ?Should neurodevelopmental monitoring be standard for children on CBD therapy?

Trust & Context

Key Stat:
The endocannabinoid system regulates neural differentiation, migration, and survival from early developmental stages - the same system modulated by CBD treatment.
Evidence Grade:
Moderate - comprehensive review of relevant biology, but concerns are largely theoretical rather than based on observed clinical harms.
Study Age:
Published in 2018. Long-term follow-up data from CBD trials in children is now beginning to emerge.
Original Title:
Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.
Published In:
CNS drugs, 32(8), 697-712 (2018)
Database ID:
RTHC-01830

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Is CBD safe for children long-term?

CBD has proven short-term benefits for severe childhood epilepsy, but this review points out that the endocannabinoid system plays critical roles in brain development. Long-term neurodevelopmental effects of modulating this system in children have not been adequately studied.

Is pure CBD safer than cannabis extract for children?

The authors suggest purified CBD may be safer than CBD-enriched cannabis extracts for young patients, since extracts also contain THC. However, they note that even pure CBD interacts with the endocannabinoid system and has many other molecular targets.

Read More on RethinkTHC

Cite This Study

RTHC-01830·https://rethinkthc.com/research/RTHC-01830

APA

Schonhofen, Patrícia; Bristot, Ivi Juliana; Crippa, José Alexandre; Hallak, Jaime Eduardo Cecílio; Zuardi, Antônio Waldo; Parsons, Richard B; Klamt, Fábio. (2018). Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.. CNS drugs, 32(8), 697-712. https://doi.org/10.1007/s40263-018-0550-4

MLA

Schonhofen, Patrícia, et al. "Cannabinoid-Based Therapies and Brain Development: Potential Harmful Effect of Early Modulation of the Endocannabinoid System.." CNS drugs, 2018. https://doi.org/10.1007/s40263-018-0550-4

RethinkTHC

RethinkTHC Research Database. "Cannabinoid-Based Therapies and Brain Development: Potential..." RTHC-01830. Retrieved from https://rethinkthc.com/research/schonhofen-2018-cannabinoidbased-therapies-and-brain

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.